Brought to you by 
Presidio gets exclusive rights to XTL's HCV compounds
29 Apr 2020
Executive Summary
XTL Biopharmaceuticals (focused on neurological and infectious diseases) licensed Presidio Pharmaceuticals (antivirals) exclusive development and commercialization rights to preclinical hepatitis C compounds targeting NS5A.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Presidio gets exclusive rights to XTL's HCV compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice